Aker Biomarine AS
Aker BioMarine ASA, a biotech innovator, develops and supplies krill-derived products for consumer health and wellness worldwide. It operates through three segments: Human Health Ingredients (HHI), Consumer Health Products, and Emerging Business. The Human Health Ingredients segment sells B2B krill oil supplements for humans under the Superba Krill brand; supplements for brain health under the LY… Read more
Aker Biomarine AS (AKBM) - Total Liabilities
Latest total liabilities as of June 2025: Nkr237.50 Million NOK
Based on the latest financial reports, Aker Biomarine AS (AKBM) has total liabilities worth Nkr237.50 Million NOK as of June 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Aker Biomarine AS - Total Liabilities Trend (2016–2024)
This chart illustrates how Aker Biomarine AS's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Aker Biomarine AS Competitors by Total Liabilities
The table below lists competitors of Aker Biomarine AS ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Renascor Resources Ltd
AU:RNU
|
Australia | AU$3.83 Million |
|
Viridis Mining and Minerals Ltd
AU:VMM
|
Australia | AU$937.46K |
|
Chip Hope Co. Ltd
TWO:8084
|
Taiwan | NT$349.93 Million |
|
Gallant Venture Ltd
PINK:GLVNF
|
USA | $1.24 Billion |
|
Paiho Shih Holdings Corp
TW:8404
|
Taiwan | NT$11.90 Billion |
|
Cambi ASA
OL:CAMBI
|
Norway | Nkr269.90 Million |
|
Nextensa NV
BR:NEXTA
|
Belgium | €815.25 Million |
|
OPTIMIZERx Corp
NASDAQ:OPRX
|
USA | $48.06 Million |
Liability Composition Analysis (2016–2024)
This chart breaks down Aker Biomarine AS's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.62 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | 0.26 | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.59 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.61 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Aker Biomarine AS's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Aker Biomarine AS (2016–2024)
The table below shows the annual total liabilities of Aker Biomarine AS from 2016 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | Nkr213.50 Million | -53.65% |
| 2023-12-31 | Nkr460.60 Million | +3.32% |
| 2022-12-31 | Nkr445.80 Million | +15.16% |
| 2021-12-31 | Nkr387.12 Million | +18.29% |
| 2020-12-31 | Nkr327.26 Million | -39.13% |
| 2019-12-31 | Nkr537.68 Million | +113.84% |
| 2018-12-31 | Nkr251.43 Million | -20.96% |
| 2017-12-31 | Nkr318.12 Million | +54.94% |
| 2016-12-31 | Nkr205.32 Million | -- |